Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176	
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al</i> .		
		Filing Date April 18, 2007	Group Art Unit 1641	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,946,778	08/07/1990	Ladner et al.			
	2	5,789,554	08/04/1998	Leung et al.		,	
	3	7,456,260	11/25/2008	Rybak et al.			
	4	2008/0248037	10/09/2008	Li et al.			
	5	2009/0117097	05/07/2009	Igawa et al.			

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Desig.	Desig.	esig. Document	Publication	Country or			Translation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	6	WO 99/12973	03/18/1999	WIPO			English abstract	
	7	WO 01/87337	11/22/2001	WIPO				
	8	WO 2004/003019	01/08/2004	WIPO				

(Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
·	9	ARNDT et al., "Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment," <i>Biochemistry</i> , 37:12918-12926 (1998)			
	10	DUFNER et al., "Harnessing phage and ribosome display for antibody optimization," Trends Biotechnol., 24(11):523-529 (2006)			
	11	ICHIKAWA <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> , 7:954-960 (2001)			
	12	KUMAR et al., "Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli," The Journal of Biological Chemistry, 275(41):35129-35136 (2000)			
	13	MATEO <i>et al.</i> , "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nat. Med.</i> , 5(11):1277-1284 (1999)			
	14	PAUL, Fundamental Immunology, 3rd Edition, Raven Press, NY, Chapter 8, pp. 292-295 (1993)			
	15	SMITH-GILL <i>et al.</i> , "Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens," <i>The Journal of Immunology</i> , 139:4135-4144 (1987)			
	16	SONG et al., "Light chain of natural antibody plays a dominant role in protein antigen binding," Biochemical and Biophysical Research Communications, 268:390-394 (2000)			
	17	WAKELEE <i>et al.</i> , "Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors," <i>Ann. Oncol.</i> On-line publication (7/24/2009)			
	18	WARD <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," <i>Nature</i> , 341:544-546 (1989)			
	19	WHITLOW <i>et al.</i> , "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," <i>Protein Eng.</i> , 7(8):1017-1026 (1994)			

Examiner Signature	Date Considered
EVANABLED 1.35-13-4 idead Dec Backback being	ting and and and appointment in all the control of this form with
EXAMINER: Initials citation considered. Draw line through citation if no	t in comormance and not considered. Include copy of this form with
next communication to applicant.	
	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176	
by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>		
		Filing Date April 18, 2007	Group Art Unit 1641	

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	20	YAGITA et al., "TRAIL and its receptors as targets for cancer therapy," Cancer Sci., 95:777-783 (2004)			
	21	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 16, 2009 in U.S. App. Ser. No. 10/550,934, filed September 10, 2009, 75 pages			
	22	FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 8, 2009 in U.S. App. Ser. No. 11/913,229, filed August 4, 2009, 1 page			
	23	J.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed September 15, 2009, 22 pages			
	24	EPO EXAMINER TERESA SOMMERFELD, European Search Report for App. Ser. No. EP 06 74 6578, dated June 25, 2009, 2 pages			
	25	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 15, 2009 in U.S. App. Ser. No. 10/551,504, filed August 14, 2009, 19 pages			
	26	KLARQUIST SPARKMAN, LLP Response to Restriction Requirement dated May 26, 2009 in U.S. App. Ser. No. 10/582,654, filed June 23, 2009, 2 pages			
	27	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. No. 10/582,654, mailed September 1, 2009, 36 pages			
	28	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed September 11, 2009, 24 pages			
	29	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/257,864, mailed February 1, 2006, 14 pages			

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				

next communication to applicant.